Price (delayed)
$1.6
Market cap
$53.71M
P/E Ratio
0.85
Dividend/share
N/A
EPS
$1.89
Enterprise value
$79.47M
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME
There are no recent dividends present for OTLK.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.